Antimicrobial Susceptibility Testing Market Expands as Rising Antimicrobial Resistance, Rapid Diagnostics, and Precision Microbiology Drive Global Growth

The Global Antimicrobial Susceptibility Testing (AST) Market is witnessing substantial growth as healthcare systems worldwide intensify efforts to combat antimicrobial resistance (AMR) through advanced diagnostic technologies. According to Maximize Market Research, the Antimicrobial Susceptibility Testing Market was valued at USD 3.76 Billion in 2023 and is projected to reach USD 5.92 Billion by 2030, growing at a CAGR of 6.7% during the forecast period.

The market is being driven by the increasing prevalence of antibiotic-resistant infections, growing demand for rapid and accurate diagnostic testing, and expanding investments in clinical microbiology laboratories. Hospitals and diagnostic laboratories are increasingly adopting automated AST systems, molecular diagnostics, artificial intelligence (AI), and laboratory automation to identify pathogens quickly and optimize antimicrobial therapy. Rising incidences of healthcare-associated infections (HAIs), bloodstream infections, respiratory diseases, urinary tract infections, and sepsis continue increasing demand for antimicrobial susceptibility testing. Furthermore, government initiatives promoting antimicrobial stewardship programs, infection prevention strategies, and surveillance of resistant pathogens are creating significant growth opportunities. Technological advances in automated microbiology instruments, rapid phenotypic testing, genomics, and AI-assisted laboratory workflows are expected to further accelerate market development.

* Request Your Free Sample Copy: https://www.maximizemarketresearch.com/request-sample/1281/ 

U.S. Market Trends and Investments 

The United States continues to dominate the global Antimicrobial Susceptibility Testing Market owing to its advanced healthcare infrastructure, strong diagnostic industry, and extensive investment in infectious disease research. During 2025, healthcare organizations and diagnostic companies significantly expanded investments in rapid antimicrobial susceptibility testing platforms, molecular diagnostics, and AI-powered laboratory automation to improve clinical decision-making and reduce inappropriate antibiotic use. Federal agencies, including the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH), continue supporting antimicrobial resistance surveillance, diagnostic innovation, and antimicrobial stewardship initiatives. Major diagnostic manufacturers are introducing faster AST platforms integrated with laboratory information systems to improve turnaround times and patient outcomes. Growing emphasis on hospital infection control and precision antimicrobial therapy continues driving sustained demand across the U.S. market.

Largest Market Segment

According to the Maximize Market Research report, the Automated Antimicrobial Susceptibility Testing Systems segment holds the largest share of the global Antimicrobial Susceptibility Testing Market. Healthcare providers increasingly prefer automated AST systems because they offer faster turnaround times, improved testing accuracy, standardized workflows, reduced manual intervention, and higher laboratory efficiency. Rising demand for rapid diagnosis of bacterial infections, increasing laboratory automation, and expanding clinical microbiology testing continue supporting the dominance of this segment.

Antimicrobial Susceptibility Testing Market, Key Players:
1. bioMérieux SA
2. Becton
3. Dickinson and Company
4. Thermo Fisher Scientific
5. Danaher Corporation
6. Bio-Rad Laboratories, Inc.
7. Bruker
8. Roche Diagnostics Limited
9. Accelerate Diagnostics, Inc.
10. Merck KGaA
11. Hi-Media Laboratories
12. Liofilchem S.r.l.
13. Alifax S.r.l.
14. Creative Diagnostics
15. Synbiosis
16. Bioanalyse
17. ZHUHAI DL BIOTECH Co., Ltd.
18. ELITechGroup
19. Mast Group Ltd.
20. CONDALAB
21. Genefluidics, Inc.
22. Biotron Ltd
23. InvivoGen
24. MP Biomedicals
25. QuantaMatrix Inc.
26. PML Microbiologicals Inc.
27. Other key players

Competitive Analysis

The global Antimicrobial Susceptibility Testing Market is highly competitive, with leading diagnostic companies investing heavily in automation, molecular diagnostics, and AI-powered microbiology platforms.

bioMérieux SA continues strengthening its leadership through continuous investment in automated microbiology systems, rapid AST platforms, and digital laboratory solutions. The company continues expanding innovation in infectious disease diagnostics and antimicrobial stewardship technologies.

Becton, Dickinson and Company (BD) has enhanced its diagnostic portfolio through advanced automated microbiology instruments, laboratory automation solutions, and rapid susceptibility testing technologies. Continued investments focus on improving workflow efficiency and accelerating clinical decision-making.

Thermo Fisher Scientific Inc. continues expanding its microbiology diagnostics portfolio by investing in molecular testing technologies, automated laboratory platforms, and high-throughput microbial identification systems supporting clinical laboratories worldwide.

Danaher Corporation (Beckman Coulter Diagnostics) continues investing in clinical microbiology automation, AI-powered laboratory informatics, and integrated diagnostic workflows that improve pathogen identification and antimicrobial susceptibility testing performance.

Bio-Rad Laboratories, Inc. continues strengthening its infectious disease diagnostics business through investments in molecular microbiology, quality control solutions, and automated laboratory technologies designed to improve diagnostic accuracy and laboratory productivity.

Regional Analysis

United States: The U.S. accounts for the largest share of the global Antimicrobial Susceptibility Testing Market due to advanced healthcare infrastructure, high laboratory automation, significant government funding for antimicrobial resistance programs, and strong adoption of rapid diagnostic technologies.

United Kingdom: The UK market continues expanding through National Health Service (NHS) antimicrobial stewardship initiatives, government investment in infectious disease surveillance, and growing adoption of advanced microbiology diagnostics.

Germany: Germany remains one of Europe's leading diagnostic markets due to its sophisticated healthcare system, strong clinical laboratory network, and government support for antimicrobial resistance monitoring and healthcare innovation.

France: France continues strengthening antimicrobial resistance management through national public health programs, hospital infection prevention initiatives, and investments in automated diagnostic laboratories.

Japan: Japan's aging population, advanced healthcare infrastructure, and government efforts to reduce antimicrobial resistance continue driving demand for automated microbiology systems and rapid susceptibility testing technologies.

China: China is emerging as one of the fastest-growing AST markets due to expanding healthcare infrastructure, rising infectious disease surveillance, government investment in laboratory modernization, and increasing awareness of antimicrobial resistance management.

Conclusion

The global Antimicrobial Susceptibility Testing Market is poised for sustained growth as healthcare systems increasingly prioritize rapid diagnostics, antimicrobial stewardship, and precision infectious disease management. Rising antimicrobial resistance, growing laboratory automation, and advances in AI-powered microbiology are transforming the diagnosis and treatment of bacterial infections. Looking ahead, rapid phenotypic testing, molecular diagnostics, integrated laboratory automation, and AI-driven clinical decision support will create significant growth opportunities across hospitals and diagnostic laboratories. Companies that continue investing in innovative diagnostic technologies, automated testing platforms, and precision microbiology solutions will be well positioned to lead the evolving global antimicrobial susceptibility testing market.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com